Poster: MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial
Year: 2021
Type: article
Authors: Oksana Zavidij, Patricia Keller, Jike Cui, Jennifer Mertz, Mohamed Salama, Horatiu Olteanu, April Chiu, Dong Chen, Curtis A Hanson, Zehua Chen, Srdan Verstovsek, Claire Harrison, John Mascarenhas, Moshe Talpaz, Ruben Mesa, Alessandro Vannucchi, Raajit Rampal, Stephen Oh, Gozde Colak, Katarina Luptakova, Jeffrey Humphrey, Jing Wang, Patrick Trojer
Institutions: Constellation Pharmaceuticals (United States), Mayo Clinic, The University of Texas MD Anderson Cancer Center, Guy's Hospital, St Thomas' Hospital, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, University of Michigan, U-M Rogel Cancer Center, Mays Cancer Center at UT Health San Antonio, Azienda Ospedaliero-Universitaria Careggi, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4200551871